LeMaitre Vascular Inc (NASDAQ:LMAT) Expected to Announce Quarterly Sales of $28.94 Million

Equities research analysts forecast that LeMaitre Vascular Inc (NASDAQ:LMAT) will announce sales of $28.94 million for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for LeMaitre Vascular’s earnings, with the highest sales estimate coming in at $29.11 million and the lowest estimate coming in at $28.70 million. LeMaitre Vascular posted sales of $27.02 million in the same quarter last year, which would suggest a positive year over year growth rate of 7.1%. The company is expected to announce its next earnings report on Thursday, July 25th.

On average, analysts expect that LeMaitre Vascular will report full-year sales of $114.10 million for the current fiscal year, with estimates ranging from $113.90 million to $114.30 million. For the next year, analysts expect that the business will report sales of $121.69 million, with estimates ranging from $120.10 million to $122.64 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that follow LeMaitre Vascular.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Wednesday, May 1st. The medical instruments supplier reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.02). LeMaitre Vascular had a net margin of 20.92% and a return on equity of 16.76%. The company had revenue of $28.48 million for the quarter, compared to the consensus estimate of $27.94 million. During the same quarter in the prior year, the firm earned $0.19 earnings per share. LeMaitre Vascular’s revenue for the quarter was up 9.6% compared to the same quarter last year.

A number of brokerages recently weighed in on LMAT. BidaskClub upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Friday, March 1st. Zacks Investment Research cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday, April 13th. ValuEngine upgraded shares of LeMaitre Vascular from a “sell” rating to a “hold” rating in a research note on Friday, April 26th. Finally, Barrington Research restated a “buy” rating and set a $32.00 price objective on shares of LeMaitre Vascular in a research note on Thursday, May 2nd. Six equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. LeMaitre Vascular presently has an average rating of “Hold” and an average target price of $31.00.

A number of institutional investors have recently modified their holdings of the business. BlackRock Inc. raised its position in LeMaitre Vascular by 2.2% in the fourth quarter. BlackRock Inc. now owns 2,601,309 shares of the medical instruments supplier’s stock worth $61,496,000 after acquiring an additional 56,161 shares in the last quarter. Conestoga Capital Advisors LLC raised its position in LeMaitre Vascular by 1.5% in the first quarter. Conestoga Capital Advisors LLC now owns 1,698,881 shares of the medical instruments supplier’s stock worth $52,665,000 after acquiring an additional 25,750 shares in the last quarter. Ranger Investment Management L.P. raised its position in LeMaitre Vascular by 1.3% in the fourth quarter. Ranger Investment Management L.P. now owns 732,380 shares of the medical instruments supplier’s stock worth $17,313,000 after acquiring an additional 9,688 shares in the last quarter. Bank of New York Mellon Corp raised its position in LeMaitre Vascular by 1.5% in the fourth quarter. Bank of New York Mellon Corp now owns 256,990 shares of the medical instruments supplier’s stock worth $6,075,000 after acquiring an additional 3,841 shares in the last quarter. Finally, Wasatch Advisors Inc. raised its position in LeMaitre Vascular by 54.2% in the first quarter. Wasatch Advisors Inc. now owns 218,784 shares of the medical instruments supplier’s stock worth $6,782,000 after acquiring an additional 76,921 shares in the last quarter. Hedge funds and other institutional investors own 77.10% of the company’s stock.

Shares of NASDAQ LMAT traded up $0.13 during midday trading on Wednesday, reaching $27.98. 232,866 shares of the company traded hands, compared to its average volume of 84,184. LeMaitre Vascular has a 52 week low of $21.79 and a 52 week high of $38.99. The stock’s 50-day moving average is $26.91. The firm has a market capitalization of $547.84 million, a P/E ratio of 33.31, a price-to-earnings-growth ratio of 2.80 and a beta of 1.17.

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 6th. Shareholders of record on Wednesday, May 22nd were given a $0.085 dividend. This represents a $0.34 annualized dividend and a yield of 1.22%. The ex-dividend date was Tuesday, May 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 40.48%.

About LeMaitre Vascular

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

See Also: What is Cost of Capital?

Get a free copy of the Zacks research report on LeMaitre Vascular (LMAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.